Journal of Clinical and Aesthetic Dermatology

Updates on Psoriasis & Cutaneou Oncology

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/882293

Contents of this Issue

Navigation

Page 37 of 43

S38 P r o c e e D i n G s JCAD jOUrnAl Of ClInICAl And AEsthEtIC dErMAtOlOgy september 2017 • volume 10 • number 9 • supplement halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J Am Acad Dermatol. 2017;16(3):197–204. 44. Mavers M, ruderman eM, Perlman H. intracellular signal pathways: potential for therapies. Curr Rheumatol Rep. 2009;11(5):378–385. 45. rommel c, camps M, Ji H. Pi3K delta and Pi3K gamma: partners in crime in ingammation in rheumatoid arthritis and beyond? Nat Rev Immunol. 2007;7(3):191– 201. 46. Ghoreschi K, Jesson Mi, li x, et al. Modulation of innate and adaptive immune responses by tofacitinib (cP- 690,550). Journal Immunol. 2011;186(7):4234–4243. 47. shuai K, liu B. regulation of JaK-stat signaling in the immune system. Nat Rev Immunol. 2003;3(11):900–911. 48. o'sullivan la, liongue c, lewis rs, stephenson se, Ward ac. cytokine receptor signaling through the Jak-stat- socs pathway in disease. Mol Immunol. 2007;44(10):2497–2506. 49. o'shea JJ, Plenge r. JaK and stat signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36(4):542–550. 50. Mcinnes iB, schett G. cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429– 442. 51. Papp Ka, Bissonnette r, Gooderham M, et al. treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol. 2016;16(1):15. 52. Punwani n, Burn t, scherle P, et al. Downmodulation of key ingammatory cell markers with a topical Janus kinase 1/2 inhibitor. Br J Dermatol. 2015;173(4):989– 997. 53. christophers e. comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529–534. 54. egeberg a, skov l, Joshi aa, et al. the relationship between duration of psoriasis, vascular ingammation, and cardiovascular events. J Am Acad Dermatol. 2017;s0190–9622(17)31925–4. 55. tula e, ergun t, seckin D, ozgen Z, avsar e. Psoriasis and the liver: problems, causes and course. The Australas J Dermatol. 2017; 58(3):194–199. 56. Jensen P, egeberg a, Gislason G, Hansen Pr, thyssen JP, skov l. increased risk of autoimmune hepatitis in patients with psoriasis: a Danish nationwide cohort study. J Invest Dermatol. 2016;136(7):1515–1517. 57. Braganza J, lee s, Mccloy r, McMahon M. chronic pancreatitis. Lancet. 2011;377:1184–1197. 58. chiu Hy, Hsieh cf, chiang yt, Huang Wf, tsai tf. the risk of chronic pancreatitis in patients with psoriasis: a population-based cohort study. PLoS One. 2016;11(7):e0160041. 59. chiu Hy, Wang it, Huang Wf, tsai yW, shiu Mn, tsai tf. increased risk of avascular necrosis in patients with psoriatic disease: a nationwide population-based matched cohort study. J Am Acad Dermatol. 2017;76(5):903–910.e901. 60. Gelfand JM, troxel aB, lewis JD, et al. the risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493–1499. 61. Prodanovich s, Kirsner rs, Kravetz JD, Ma f, Martinez l, federman DG. association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700–703. 62. Balci DD, Balci a, Karazincir s, et al. increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad of Dermatol and Venereol. 2009;23(1):1–6. 63. Pina t, corrales a, lopez-Mejias r, et al. anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stidness in patients with moderate to severe psoriasis: a 6-month prospective study. J Dermatol. 2016;43(11):1267–1272. 64. Hjuler Kf, Bottcher M, vestergaard c, Botker He, iversen l, Kragballe K. association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol. 2016;152(10):1114–1121. 65. Wu JJ, Guerin a, sundaram M, Dea K, cloutier M, Mulani P. cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90. 66. Bos JD, Hulsebosch HJ, Krieg sr, Bakker PM, cormane rH. immunocompetent cells in psoriasis. in situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983;275(3):181–189. 67. Bos JD, Hagenaars c, Das PK, Krieg sr, voorn WJ, Kapsenberg Ml. Predominance of "memory" t cells (cD4+, cDw29+) over "naive" t cells (cD4+, cD45r+) in both normal and diseased human skin. Arch Dermatol Res. 1989;281(1):24–30. 68. Gottlieb sl, Gilleaudeau P, Johnson r, et al. response of psoriasis to a lymphocyte-selective toxin (DaB389il-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1(5):442–447. 69. Kadenberger BH, Kadenberger tM, Wong HK. immunotargeting in the management of psoriasis. ImmunoTargets Ther. 2013;2:51–60. 70. Ganguly D, chamilos G, lande r, et al. self-rna- antimicrobial peptide complexes activate human dendritic cells through tlr7 and tlr8. J Exp Med. 2009;206(9):1983–1994. 71. lande r, Gregorio J, facchinetti v, et al. Plasmacytoid dendritic cells sense self-Dna coupled with antimicrobial peptide. Nature. 2007;449(7162):564–569. 72. Blanco P, Palucka aK, Gill M, Pascual v, Banchereau J. induction of dendritic cell diderentiation by ifn-alpha in systemic lupus erythematosus. Science. 2001;294(5546):1540–1543. 73. Zaba lc, Krueger JG, lowes Ma. resident and "ingammatory" dendritic cells in human skin. J Invest Dermatol. 2009;129(2):302–308. 74. lowes Ma, chamian f, abello Mv, et al. increase in tnf- alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-cD11a). Proc Natl Acad Sci U S A. 2005;102(52):19057–19062. 75. chamian f, lowes Ma, lin sl, et al. alefacept reduces infltrating t cells, activated dendritic cells, and ingammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 2005;102(6):2075–2080. 76. tonel G, conrad c, laggner u, et al. cutting edge: a critical functional role for il-23 in psoriasis. J Immunol. 2010;185(10):5688–5691. 77. Mangan Pr, Harrington le, o'Quinn DB, et al. transforming growth factor-beta induces development of the t(H)17 lineage. Nature. 2006;441(7090):231–234. 78. Morishima n, Mizoguchi i, takeda K, Mizuguchi J, yoshimoto t. tGf-beta is necessary for induction of il- 23r and th17 diderentiation by il-6 and il-23. Biochem Biophys Res Commun. 2009;386(1):105–110. 79. nograles Ke, Zaba lc, Guttman-yassky e, et al. th17 cytokines interleukin (il)-17 and il-22 modulate distinct ingammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092–1102. 80. chiricozzi a, Guttman-yassky e, suarez-farinas M, et al. integrative responses to il-17 and tnf-alpha in human keratinocytes account for key ingammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677– 687. 81. Krueger JG, fretzin s, suarez-farinas M, et al. il-17a is essential for cell activation and ingammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–154 e149. 82. Boniface K, Guignouard e, Pedretti n, et al. a role for t cell-derived interleukin 22 in psoriatic skin ingammation. Clin Exp Immunol. 2007;150(3):407–415. 83. Boniface K, Bernard fx, Garcia M, Gurney al, lecron Jc, Morel f. il-22 inhibits epidermal diderentiation and induces proingammatory gene expression and migration of human keratinocytes. J Immunol. 2005;174(6):3695– 3702. 84. Wilson nJ, Boniface K, chan Jr, et al. Development, cytokine profle and function of human interleukin 17- producing helper t cells. Nat Immunol. 2007;8(9):950–957. 85. Zhang W, Dang e, shi x, et al. the pro-ingammatory cytokine il-22 up-regulates keratin 17 expression in keratinocytes via stat3 and erK1/2. PloS One. 2012;7(7):e40797. 86. oestreicher Jl, Walters iB, Kikuchi t, et al. Molecular classifcation of psoriasis disease-associated genes through pharmacogenomic expression profling. Pharmacogenomics J. 2001;1(4):272–287. 87. suarez-farinas M, li K, fuentes-Duculan J, Hayden K, Brodmerkel c, Krueger JG. expanding the psoriasis disease profle: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(11):2552–2564. 88. Wolk K, Witte e, Wallace e, et al. il-22 regulates the expression of genes responsible for antimicrobial defense, cellular diderentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006;36(5):1309–1323. 89. Wolk K, Kunz s, Witte e, friedrich M, asadullah K, sabat r. il-22 increases the innate immunity of tissues. Immunity. 2004;21(2):241–254. 90. sa sM, valdez Pa, Wu J, et al. the edects of il-20

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Updates on Psoriasis & Cutaneou Oncology